# Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

> **NCT01262391** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 42 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Solifenacin succinate suspension 2.5 mg
- **DRUG:** Solifenacin succinate suspension 5 mg
- **DRUG:** Solifenacin succinate suspension 10 mg

## Key facts

- **NCT ID:** NCT01262391
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-20
- **Primary completion:** 2011-08-14
- **Final completion:** 2011-08-14
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262391, "Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01262391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*